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ABSTRACT Ac ute myocardial infarction (AMI) is the leading 
cause of death and disability worldwide. Timely reperfusion 
is the standard of care and results in decreased infarct 
size, improving patient survival and prognosis. However, 
25% of patients proceed to develop heart failure (HF) after 
myocardial infarction (MI) and 50% of these will die within 
ﬁ ve years. Since the size of the infarct is the major predictor 
of the outcome, including the development of HF, therapies 
to improve myocardial salvage have great potential. Over the 
past three decades, a number of stimuli have been discovered 
that activate endogenous cardioprotective pathways. In 
ischemic preconditioning (IPC) and ischemic postconditioning, 
ischemia within the heart initiates the protection. Brief 
reversible episodes of ischemia in vascular beds remote from 
the heart can also trigger cardioprotection when applied 
before, during, or immediately after myocardial ischemia—
known as remote ischemic pre-, per-, and post-conditioning, 
respectively. Although the mechanism of remote ischemic 
preconditioning (RIPC) has not yet been fully elucidated, 
many mechanistic components are shared with IPC. The 
discovery of RIPC led to research into the use of remote 
non-ischemic stimuli including nerve stimulation (spinal and 
vagal), and electroacupuncture (EA). We discovered and, 
with others, have elucidated mechanistic aspects of a non-
ischemic phenomenon we termed remote preconditioning 
of trauma (RPCT). RPCT operates via neural stimulation of 
skin sensory nerves and has similarities and differences to 
nerve stimulation and EA conducted at acupoints. We show 
herein that RPCT can be mimicked using electrical stimulation 
of the abdominal midline (EA-like treatment) and that this 
modality of activating cardioprotection is powerful as both 
a preconditioning and a postconditioning stimulus (when 
applied at reperfusion). Investigations of these cardioprotective 
phenomena have led to a more integrative understanding of 
mechanisms related to cardioprotection, and in the last five 
to ten years, it has become clear that the mechanisms are 
similar, whether induced by ischemic or non-ischemic stimuli. 
Taking together much of the data in the literature, we propose 
that all of these cardioprotective “conditioning” phenomena 
represent activation from different entry points of a cardiac 
conditioning network that converges upon speciﬁ c mediators 
and effectors of myocardial cell survival, including NF -κB, 
Stat3/5, protein kinase C, bradykinin, and the mi toKATP channel. 
Nervous system pathways may represent a novel mechanism 
for initiating conditioning of the heart and other organs. IPC 
and RIPC have proven difficult to translate clinically, as they 
have associated risks and cannot be used in some patients. 
Because of this, the use of neural and nociceptive stimuli 
is emerging as a potential non-ischemic and non-traumatic 
means to initiate cardiac conditioning. Clinical relevance is 
underscored by the demonstration of postconditioning with 
one of these modalities, supporting the conclusion that the 
development of pharmaceuticals and electroceuticals for this 
purpose is an area ripe for clinical development.
KEYWORDS remote cardioprotection, cardiac conditioning, 
non-ischemic conditioning, peripheral nociceptive stimulus, 
neural and molecular mechanism, clinical feasibil ity, 
electroceuticals
1 Introduction
In 1986, Murry et al. [1] ﬁ rst described ischemic preconditioning 
(IPC), in which brief episodes of ischemia/reperfusion (I/R) 
preceded an injurious I/R resulting in reduced myocardial 
infarct size in a canine model. The phenomenon of IPC has 
since been successfully demonstrated in multiple animal 
species including dogs, rats, pigs, rabbits, and mice, as well 
as confirmed in human patients [2–7]; reviewed in Ref. [8]. 
Marber et al. [9] reported a second window of protection (late 
preconditioning), which develops 12–24 h after the initial 
preconditioning stimulus. Unlike early IPC, which is power-
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ful but short-lived, late IPC remains protective for 24–72 h, 
although the magnitude of the protection is less over time [3]. 
Repeated preconditioning episodes of the same type are nei-
ther additive nor cumulative [10].
In 1993, Przyklenk et al. [11] demonstrated that in the ca-
nine heart, a preconditioning stimulus applied to the vascular 
bed supplied by the circumﬂ ex branch reduced infarct size in 
the area of the myocardium supplied by the left anterior de-
scending coronary artery. Subsequently, it was demonstrated 
by McClanahan et al. [12] that cardioprotection could even be 
achieved by preconditioning ischemic stimuli in distant organ 
sites, such as the kidney. Remote ischemic preconditioning 
(RIPC) has been demonstrated to elicit cardioprotection fol-
lowing ischemia of kidneys, intestine, limbs, liver, skeletal 
muscle, and brain (reviewed in Ref. [13]). While the release 
of diffusible factors from ischemic preconditioned tissues/
organs is a key aspect of RIPC [14–18], it is also evident that 
neural connections to the preconditioned limb or tissue are 
required. For instance, it has been shown in most [19] but not 
all [20] animal models that blocking sympathetic transmission 
using hexamethonium abrogates RIPC’s protective effect. In a 
mouse hindlimb model, it has been demonstrated that either 
occlusion of the femoral vein or transection of the femoral and 
sciatic nerves likewise abolishes the cardioprotection observed 
after RIPC, indicating the requirement for both humoral and 
neural pathways [21]. RIPC has been shown to improve short- 
and long-term clinical outcomes when applied prior to emer-
gency or elective percutaneous intervention [22], coronary ar-
tery bypass grafting [23], and valve replacement [24]. Many of 
the detailed mechanistic aspects of RIPC are shared with IPC 
(see below). Although IPC and RIPC have emerged as power-
ful methods of ameliorating I/R injury to the myocardium, 
their use as clinical cardioprotective strategies to attenuate the 
pathophysiological consequences of I/R injury (i.e., infarction 
and ventricular dysfunction) is limited by the inability to pre-
dict the onset of clinical ischemia.
As a direct result of considering this limitation, Zhao et al. 
[25] demonstrated that rapid sequential intermittent interrup-
tion of coronary blood ﬂ ow during the early moments of re-
perfusion after ischemia attenuates I/R injury. This phenom-
enon, termed postconditioning, is extremely valuable in that 
it supports the efﬁ cacious use of repetitive ischemia at a clini-
cally relevant time point (e.g., at reperfusion) [26]. The more 
recent ﬁ ndings in this ﬁ eld [27–30] have combined postcon-
ditioning and RIPC concepts by demonstrating that ischemia 
of a remote site (such as a limb) can elicit cardioprotection at 
reperfusion. A related phenomenon, perconditioning, results 
from administering a cardioprotective stimulus during the 
I/R injury [31, 32]. Remote perconditioning involves using 
a conditioning stimulus at a remote site during myocardial 
infarction (MI), and has been shown to be protective and to 
have clinical value [24]. However, all of these cardioprotective 
strategies have a limitation in that they require the use of an 
ischemic stimulus to an organ; this is often not clinically de-
sirable. Furthermore, clinical trials of such approaches have 
been disappointing [33], and/or come with significant limi-
tations and risks that prevent their use [34, 35]. The clinical 
trials of remote ischemic conditioning have some limitations, 
mainly as a result of including too few subjects, and of con-
founding variables inherent within the patient population. 
The patients involved are of heterogeneous age and overall 
health; many have co-morbidities that are known to reduce 
the efﬁ cacy of cardioprotection, and are administered drugs 
that mask or block cardioprotection [8]. Furthermore, factors 
such as collateral circulation and spontaneous or very early 
clinical reperfusion can lead to small infarcts that do not ben-
eﬁ t from adjunctive therapy [13].
Even though recent results with limb ischemia have sup-
ported cardioprotection in humans [36], this approach can be 
difﬁ cult to tolerate and cannot be employed in some patients, 
including the morbidly obese, or patients who have had axial 
lymphadenectomy. An alternative would be to achieve car-
dioprotection using a non- or minimally-invasive technique, 
such as a remote non-ischemic stimulus. Cardioprotection 
has been shown to result from non-ischemic stimuli includ-
ing nerve stimulation (spinal, vagal, femoral), acupuncture 
and electroacupuncture, skin incision, and the chemical or 
electrical treatment of skin [37–43]. To the extent that some of 
these modalities are less traumatic yet efficacious, they are 
being studied as potential therapies.
2 IPC, RIPC, and cardiac conditioning
Over the past 25 years, we have learned a great deal about 
the detailed mechanisms that underlie cardioprotection in 
general, and IPC, RIPC, and related phenomena speciﬁ cally. 
Mechanistic studies usually focus upon initiators, mediators, 
and effectors of protection, though over the years, our in-
sights have blurred some of these distinctions.
Clearly, understanding the mechanism of cardioprotec-
tion after IPC, RIPC, and postconditioning has the potential 
to elucidate potential therapeutic targets that could be used 
to initiate or intensify cardioprotection. These targets could 
be useful in preconditioning in certain situations, including 
preventing/reducing perisurgical MI and treating patients at 
risk for MI [5, 44, 45]. Alternatively, understanding the mech-
anism may be the key to discovering more clinically applica-
ble ways to initiate perconditioning and/or postconditioning 
in the clinical setting. Generally speaking, similar—yet not 
identical—mechanisms underlie the mediator and effector 
aspects of diverse protective stimuli including IPC, RIPC, 
preconditioning, postconditioning, and perconditioning 
[46]. The most diverse aspect of cardioprotective phenomena 
seems to be in the initiating phase, but this may simply rep-
resent the point of stimulation in a more general convergent 
mechanism. There are some distinct mechanistic differences 
and speciﬁ c pathways that have been shown not to be neces-
sary for certain types of cardioprotective stimuli. Combinato-
rial studies (use of multiple stimuli) have sometimes shown 
additive effects supporting mechanistic differences [47, 48]. 
However, other combinations have not shown such effects, 
supporting a similarity or at least an overlap of mechanism. 
In this paper, we compare and contrast some of these data, 
extract some meaning, and add to what is known in a way 
that may point to more efﬁ cacious and practical types of car-
dioprotection to invoke in a clinical setting.
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Some studies of combinatorial stimuli are shown as fol-
lows. In recent years, there have been several studies com-
bining conditioning stimuli in order to determine if there 
is overlapping, additive, or synergistic protection. Several 
groups have studied the combinatorial effects of postcondi-
tioning and perconditioning. The rationale for such studies 
is that the reduction in infarct size by either stimulus is often 
less than that of preconditioning. Given the greater clinical 
relevance of these stimuli, any additivity would be of inter-
est. Xin et al. [47] ﬁ rst studied combinatorial effects in 2010. 
They found that postconditioning and perconditioning, 
while each less protective than preconditioning, additively 
mimicked the extent of protection afforded by precondition-
ing. Furthermore, they found that combining the effects of 
preconditioning with those of the postconditioning plus 
perconditioning combination resulted in no further protec-
tion, suggesting that preconditioning and the postcondition-
ing/perconditioning combination have similar overlapping 
mechanisms. Studies of kinase activity showed the activa-
tion of Akt and ERK1/2 phosphorylation by all stimuli, but 
that the extent of activation was highest in IPC and was 
mimicked by the postconditioning plus perconditioning 
combination. In each instance, protection was blocked by 
PI3K or ERK1/2 inhibitors. Xin et al. concluded that the stim-
uli, which differ in the timing of initiation, work through the 
same general mechanisms and that it is the extent of kinase 
activation that confers the extent of protection in mice. This 
conclusion is consistent with mechanistic studies of these 
phenomena, and with a study by the same group showing 
that repeated remote postconditioning stimuli increase the 
extent of cardioprotection [49]. Interestingly, Tamareille et al. 
[30] found that IPC and RIPC act additively to reduce infarct 
size, but that, in addition to the activation of reperfusion 
injury salvage kinase (RISK) pathways, the addition of RIPC 
resulted in increased levels of phospho-Stat3. They conclud-
ed that the mechanisms of IPC and RIPC were overlapping 
but that they were somewhat different. However, it must 
be noted that a requirement for Stat3 has independently 
been established for IPC [50, 51]. A study by Kloner’s group 
showed that perconditioning and remote postconditioning 
were not effective in the rat model used, obviating the ques-
tion of the combination in that case [52]. The recent remote 
ischemic postconditioning (RIPOST) clinical trial showed 
that remote perconditioning and postconditioning were both 
effective, but that the combination did not produce a signiﬁ -
cant additive effect (reduction in creatinine kinase-MB (CK-
MB) AUC from 31% to 29%, P > 0.05) [48]. Thus, the evidence 
of combinatorial studies in animal models and in humans 
supports the concept that overall, protective pathways work 
by overlapping if not similar mechanisms. Because of the 
growing recognition of this concept in the field, the term 
“conditioning” is coming into vogue as a general term to re-
fer to these types of effects.
3 Novel methods of initiating cardiac conditioning
In addition to cardiac ischemia, which initiates IPC, and 
ischemia elsewhere, including limb ischemia, which initiates 
RIPC to the heart, several non-ischemic stimuli have been 
studied as initiators of cardiac conditioning, notably elec-
troacupuncture (EA), skin incision, and the pharmacological 
activation of skin nociception. We review these stimuli here 
due to their potential clinical relevance, and for what they 
can tell us about the mechanism of cardiac conditioning. We 
primarily discuss the effects of EA, spinal stimulation, vagal 
stimulation, and skin nociceptor activation, all of which are 
able to activate cardiac conditioning. This work was pre-
saged by three papers from the late 1980s and early 1990s 
that showed the adaptive effects of EA and vagal stimulation 
upon the heart [53–55]. In particular, the paper published in 
1991 by Meerson et al. showed that EA of an isolated heart re-
duced necrosis. Subsequently, several investigators observed 
a role for nerves and neuropeptides in conditioning phenom-
ena. The peptide bradykinin is well known to be required for 
ischemic pre- and post-conditioning [56, 57], and Erşahin et 
al. and Sho emaker et al. ﬁ rst showed its involvement in RIPC 
[58, 59]. Bradykinin is involved in sensory nerve signaling, 
and cardiomyocytes have the BKR2 receptor for bradykinin. 
In the rat model, bradykinin in the coronary circulation is de-
graded quickly by angiotensin converting enzyme (ACE) and 
by aminopeptidase P. Erşahin et al. [58] showed that apstatin, 
an aminopeptidase P inhibitor, is cardioprotective against I/R 
injury in an isolated rat heart model, supporting the idea that 
the local action of bradykinin is protective, but not ruling out 
effects of systemic bradykinin. 
The Vatners’s group later showed that innervation and 
speciﬁ cally the α1-AR is required for the late phase of IPC in 
a porcine model, but that the early phase of IPC is indepen-
dent of this pathway [60]. RIPC is known to require intact in-
nervation from the ischemic bed; while there is evidence for 
hormonal mediators, it appears that neural signals are criti-
cal as well [61]. In addition to neural involvement in ischemic 
stimuli, all known forms of non-traumatic/non-ischemic 
remote conditioning involve the neural system at some level. 
EA is now thought to work through the stimulation of skin 
sensory or other innervation. Vagal and spinal stimulation 
invoke the direct stimulation of nerves. We have shown that 
skin nociception-induced conditioning (NIC), whether by 
skin incision (remote preconditioning of trauma, or RPCT), or 
chemical nociceptor stimulation, involves the stimulation of 
skin sensory nerves [42, 62]. This phenomenon likely has both 
neural and humoral components, but the relative contribu-
tion of these to the protection observed is unknown. Most of 
these non-ischemic cardiac conditioning stimuli are capable 
of initiating both an immediate protection (i.e., early phase) 
and a longer lasting protection (i.e., late phase). As will be 
seen, all of the non-ischemic remote initiators of conditioning 
seem to involve neural and hormonal mechanistic aspects. In 
this, they are similar to RIPC. However, remote percondition-
ing and postconditioning are more similar to the early phase 
in their timing of action (immediate onset of protection).
3.1 Spinal cord stimulation
Activation of the spinal dorsal horn neurons by spinal cord 
stimulation (SCS) is known to be effective in treating chronic 
intractable angina pectoris. In addition to pain relief, clini-
cal studies using SCS for the treatment of chronic refractory 
angina demonstrate increases in exercise tolerance, improve-
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ments in ischemia-related EKG changes, and improvements 
in the quality of life [37, 63, 64]. Animal studies also indicate 
that SCS improves the function of the heart. It has been dem-
onstrated that SCS reduces infarct size in a rabbit model with 
transient coronary artery occlusion, an effect that can be pre-
vented by adrenergic blockers [65]. However, this effect was 
not observed when performed as a postconditioning stimu-
lus. This result, along with the invasive nature of the proce-
dure, limits its clinical applicability, although SCS is being 
studied and has other potential uses, such as in heart failure 
(HF) and arrhythmia.
3.2 Vagal stimulation
It has long been recognized that balance of the autonomic 
nervous system is critical to many aspects of homeostasis 
and functional regulation in the heart. After myocardial 
ischemia, there is an imbalance between the sympathetic and 
parasympathetic systems, and increased chronic sympathetic 
activity is thought to contribute to mortality after MI and in 
HF [66–68]. Vagal stimulation has been studied for its poten-
tial to slow left ventricle (LV) remodeling and improve heart 
function and survival in post-MI HF. Based on this potential, 
Kong et al. [38] showed that vagal stimulation reduces infarct 
size and improves function in a rat MI model. The mecha-
nism they describe includes the activation of protein kinase 
C (PKC), nitric oxide (NO) production, and anti-inflamma-
tory effects that are not dissimilar to those that have been 
described after IPC and RIPC [38]. It has been demonstrated 
that transection of the femoral nerve likewise abolishes the 
cardioprotection of RIPC [61] and that stimulation of the 
femoral nerve can mimic RIPC of limb ischemia as well [39], 
supporting the concept that neural pathways are common to 
many forms of cardiac conditioning and that direct stimula-
tion of some nerves can elicit cardioprotection.
3.3 Electroacupuncture (EA)
In 2003, Tsou et al. [69] showed that EA at the Neiguan acu-
points (corresponding to a part of the human wrist area, in-
nervated by the thoracic vertebral region) reduces I/R injury, 
measured by reduced cardiac enzymes in a rat model. They 
also showed that this effect was blocked by the severing of 
the bilateral median nerve, the bilateral severing of the va-
gus, or by IV naloxone, implicating neural pathways, includ-
ing the vagus, whose stimulation is already known to be ca-
pable of conditioning. Wang et al. [70] demonstrated that EA 
induces cardiac conditioning against MI and that this effect 
adds to the protective effect of hypothermia, suggesting com-
plementary mechanisms. In 2006, Gao et al. [40] showed that 
EA at bilateral Neiguan acupoints is cardioprotective, reduc-
ing infarct size in a rat model by nearly 50%. This effect was 
blocked by propranolol, revealing dependency upon the ad-
renergic signaling. In 2012, Zhou et al. [41] showed in a rabbit 
model that perconditioning by EA (EA during coronary oc-
clusion) reduced infarct size concomitant with the release of 
cardiac norepinephrine (NE), and that this protection was re-
duced by the pharmacologic blockade of PKC and opioid re-
ceptors in an additive manner. This work implicates many of 
the same signaling pathways involved in IPC/RIPC, as well 
as the neural signaling in EA-induced conditioning. Reding-
ton’s group, which had previously shown the involvement of 
a dialyzable circulating factor in RIPC [61], showed that such 
is also produced in the rabbit after bilateral EA at the Nei-
guan points [71]. Despite more than 15 years of research, the 
humoral factor(s) have never been identiﬁ ed. Other work has 
implicated roles for Hsp70 (also critical for IPC and RIPC [72, 
73]) and miR-214 (also involved in ischemic postconditioning 
[74, 75]), supporting the idea that in addition to common sig-
naling and neural pathways, gene regulatory pathways may 
be common to these different forms of cardiac conditioning. 
To date, EA has not been shown to be effective as a postcon-
ditioning stimulus, but the perconditioning protection may 
have clinical relevance [41].
3.4 Initiating cardioprotection by sensory nerve activation: RPCT and 
NIC
In 2004, we published a paper describing a cardioprotective 
effect of skin surgical incision and coined the term remote 
preconditioning of trauma (RPCT) for the effect. Brieﬂ y, we 
found that a surgical incision in the abdominal peri-umbilical 
region elicited cardioprotection against a subsequent isch-
emic insult, resulting in an 80% to 85% reduction of cardiac 
infarct size. Unlike either IPC or RIPC, RPCT is ischemia-
independent and yet is highly efﬁ cacious. Like RIPC, RPCT 
requires intact neural connections [42]. RPCT has both an 
early and late phase, like IPC; however, unlike IPC, both the 
early and late phases of remote preconditioning of trauma 
are TNF-α and iNOS independent [42, 62, 76]. This shows that 
RPCT is not mechanistically identical to IPC; however, as we 
will see, there is mechanistic overlap. 
An unusual aspect of RPCT is that the initiation of the 
protective phenomenon is associated with peripheral nerve 
stimulation of a particular site—the skin bilaterally located 
around the umbilicus [42, 62]. We showed that this stimulus 
acts though skin sensory nerves, as the effect is blocked by 
topical lidocaine and mimicked by topical capsaicin cream, 
with the effect of topical capsaicin being completely blocked 
in TRPV1 knockout mice [42]. This result implicates neural 
pathways, and indeed, we showed that transection of the 
spine at the T7 vertebral level blocks protection, while C7 
transection does not, demonstrating a lack of central nervous 
system (CNS) regulation, but the necessity of spinal integrity 
between the umbilicus and the heart. Based upon the fact 
that skin nociception is the initiator of this protection, and 
that chemical and other pain initiators can activate it, we 
have coined the term nociception-induced conditioning (NIC) 
to refer to the broader phenomenon (activated by incision, 
chemical, or as we shall see, electrical means). 
Further work showed that the neural pathway could be 
traced via injection of a fluorescent dye, 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindocarbocyanine (DiI) at the skin inci-
sion site. The DiI signal was shown to stain the dorsal horns 
at both the T1–T5 (abdomen) and T9–T10 (cardiac) vertebral 
levels. This result suggests a neural pathway from the skin 
sensory nerves to the spinal dorsal root ganglia (DRG) at the 
level of the skin incision to the level of the cardiac innerva-
tion [42]. The literature supports the idea that a dorsal root 
reflex induced by peripheral nociceptive stimulation may 
form the basis of the interactions between the somatosensory 
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and cardiac sympathetic systems at different spinal levels [77, 
78]. The dorsal root reﬂ ex is a volley of action potentials that 
can be recorded emerging antidromically from the spinal 
cord in the dorsal roots following the electrical stimulation 
of an adjacent dorsal root or sensory nerve. The dorsal root 
reﬂ ex is thought to arise on the rising phase of the primary 
afferent depolarization (PAD) generated within the terminals 
of afferent ﬁ bers in the cord by a synchronous afferent vol-
ley arriving in the cord after electrical stimulation of sensory 
nerves and roots [79, 80]. This causes depolarization of the 
terminals of the afferent ﬁ bers within the cord beyond their 
threshold, producing action potentials that travel antidromi-
cally out of the cord along the dorsal roots. Spreading of the 
dorsal root reflex both along and across the cord has been 
noted by several groups [81, 82]. In an isolated hamster spinal 
cord, the dorsal root reflex has been shown to spread over 
at least fifteen segments from the lower lumbar to upper 
thoracic roots, in both rostro-caudal and caudo-rostral direc-
tions [82]. This suggests the existence of a pathway within the 
mammalian cord for the transmission of PAD between seg-
ments. The involvement of this pathway is supported by our 
spinal transection results [42]. The fact that both Hoe 140 and 
propranolol block cardioprotection, as does the genetic abla-
tion of BKR2, supports the involvement of bradykinin and 
adrenergic signaling, as was found for IPC and RIPC [59, 60]. 
We also showed a requirement for PKC activation and activ-
ity of the mitoKATP channel, supporting the hypothesis that 
common mediators and end-effectors are involved in NIC [42] 
and IPC [83]. The blockade of calcitonin gene-related pep-
tide (CGRP) and substance P signaling supports a pathway 
whereby the antidromal activation of cardiac sensory nerves 
activates cardiac sympathetic nerves. NE and bradykinin 
likely then act upon cardiomyocytes and are the activation 
signals for PKC. The Gross’s lab and others [84, 85] have con-
ﬁ rmed that RPCT (which we now see as one sort of stimulus 
for NIC) operates in dogs and rats, and have conﬁ rmed the 
requirement of bradykinin signaling. While the pharmaco-
logic blockade of adenosine and opioid signaling had no ef-
fect upon cardioprotection, unlike in IPC. Gross et al. showed 
that signaling by epoxyeicosatrienoic acids (EETs) are impor-
tant downstream of bradykinin signaling in NIC (induced by 
either RPCT or topical capsaicin) and have previously shown 
EETs to be involved in IPC and ischemic postconditioning 
[85–87]. Although EETs are thought to act locally in an auto-
crine or paracrine manner, longer-distance actions cannot yet 
be ruled out in NIC. Finally, using a topical inhibitor of PKCγ 
[88], which is a neuron-specific PKC isoform, they blocked 
NIC, conﬁ rming the role of skin nerve ﬁ bers and providing a 
new pharmacologic target for inducing NIC [86].
We believe that the published evidence supports a mecha-
nism for NIC whereby the activation of skin nociceptors at 
the anterior abdominal location (near T9–T10) sends a signal 
f rom the DRG at T9–10 to the DRG at T1–5, and that this initi-
ates an antidromic signal via cardiac sensory nerves to the 
heart. In the heart, the sensory nerves would release CGRP 
and substance P, which would trigger the release of NE from 
sympathetic nerves and bradykinin from either the sensory 
or sympathetic nerves [89]. NE and/or bradykinin would act 
in part upon cardiomyocytes, triggering PKC activation that 
would mediate the signaling and activation of end-effectors, 
including the mitochondrial KATP channels [42, 85]. This sym-
pathetic system-mediated cardiac conditioning is triggered in 
response to “warning signals” relayed by the cord from the 
remote skin nerves.
Although there is a great deal of overlap between the 
mechanisms of IPC, RPCT, and NIC, it is notable, based on 
our limited data at present, that NIC does not employ TNF-α, 
adenosine, or opioid signaling [62, 85], while IPC requires 
each of these. Interestingly, sympathetic activation, bra-
dykinin, and β-adrenergic signaling have been implicated 
in NIC and IPC, PKC seems to be required for all of these 
conditioning modalities, and CGRP has been shown to be 
cardioprotective, and to be involved in RIPC, postcondition-
ing, and cardioprotection after heat stress [90–93]. Overall, 
the available evidence supports the hypothesis that cardiac 
conditioning phenomena share aspects of mechanism while 
not requiring completely identical molecules. We propose 
that this is indeed the case and that different cardioprotec-
tive phenomena essentially represent different entry points 
into a large signaling network consisting of receptors, kinase 
and metabolic signaling cascades, gene networks, and ef-
fector pathways (Figure 1). Each type of conditioning signal 
activates this network at a distinct “edge” of the network, 
Figure 1. The “Cardiac Conditioning Network” construct postulates that 
a portion of the cellular informational network is activated on different 
edges by different stimulus, leading to convergent signaling that results in 
myocardial salvage. The conceptual diagram is not meant to be comprehensive, 
but to point out similarities that convey the concept. Abbreviations: IPC, ischemic 
preconditioning; RIPC, remote ischemic preconditioning; EA, electroacupuncture; 
RPCT, remote preconditioning of trauma; TNF-α, tumor necrosis factor alpha; 
iNOS, inducible nitric oxide synthase; CGRP, calcitonin gene-related peptide; 
PKC, protein kinase C; NE, norepinephrine; EETs, epoxyeicosatrienoic acids; 
mitoKATP, mitochondrial potassium ATPase; NF-κB, nuclear factor kappa B.
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with the consequence that speciﬁ c portions of it are the focus 
of detectable signaling pathways that converge upon more 
common protective effector pathways. The common mediator 
and effector pathways seem to include bradykinin (discussed 
above), PKC, and mitoKATP.
3.5 Protein kinase C (PKC)
PKC plays an integral role in many of the signaling cascades 
that govern cellular behavior [94]. The current paradigm of 
PKC signaling in cardioprotection has been primarily for-
mulated on the basis of information acquired through the 
pharmacologic inhibition of various signaling elements. In 
support of this linear paradigm of PKC signaling, the activa-
tion of multiple proteins in a PKC-dependent fashion has been 
demonstrated in response to IPC [95] and RIPC [96], indicat-
ing that these proteins may be signaling elements in the PKC 
pathway. As it is one of the most highly expressed myocardial 
PKC isoforms [95], PKC-α is the least studied because, unlike 
the novel isoforms PKC-δ and -ε, it is not regulated in acute 
myocardial ischemia. Translocation modification has con-
ﬁ rmed that PKC-δ is a critical mediator of post-ischemic car-
diomyocyte necrosis and contractile dysfunction in mice, rats, 
and pigs [97, 98], although the activity in the porcine model is 
disputed by one study [99]. In the normal myocardium, PKC-ε 
forms signaling complexes with at least 36 different proteins 
that can be classified as structural elements, signaling mol-
ecules, and stress-responsive proteins [100]. PKC-ε dependent 
cardioprotection induces dynamic modulation of these com-
plexes, suggesting a functional role for these complexes in the 
genesis of protection against ischemic injury [94, 101].
3.6 Mitochondrial/sarcolemmal KATP channels
Mitochondria play an important part in myocyte energy 
production through oxidative phosphorylation. They are also 
involved in key aspects of cardiomyocyte survival, through 
regulating intracellular reactive oxygen species (ROS) gen-
eration, calcium homeostasis, and the release of apoptosis-
inducing factors [102–104]. Both mitoKATP and sarcKATP chan-
nels are present in the mammalian heart [105] and appear 
to be involved in IPC and cardioprotection [102]. Gaudette et 
al. [106] demonstrated in a sheep model that protection pro-
vided by direct mitoKATP openers could be abolished by PKC 
antagonists (chelerythrine); and that protection mediated via 
the activation of PKC could be abrogated by administration 
of the mitoKATP channel antagonist 5-hydroxydecanoate (5-
HD), a selective blocker of the mitoKATP channels, implying 
that the activation of PKC and of mitoKATP channels are both 
codependent and necessary for protection in the heart. No-
zawa et al. [107] showed that IPC in rats produced a translo-
cation of both PKC-ε and PKC-δ; however, 5-HD blocked the 
effect of IPC without blocking the translocation of the two 
PKC isoforms. These results suggest that the mitoKATP chan-
nel or the site of action of 5-HD is distal to PKC. The mitoKATP 
is one of the major and likely common effector pathways 
for improving cell survival after I/R injury. However, as for 
other pharmacologic inducers of cardiac conditioning, severe 
limitations exist on the clinical utility of drugs targeting this 
channel.
4 The potential clinical utility of NIC and EA
As mentioned earlier in this paper, EA has not been shown to 
be useful for cardiac postconditioning; however, one positive 
study supports its use as a perconditioning stimulus [41]. Be-
cause of mechanistic similarities, and because of the limited 
clinical utility of RPCT (i.e., involving surgical skin incision), 
we sought an easier, non-traumatic way to initiate NIC by 
abdominal sensory nerve activation using electrical stimula-
tion—EA of the skin in this instance. We tested the hypoth-
esis that remote electrical stimulation of the same skin ﬁ eld 
stimulated using RPCT and NIC (with capsaicin [42]) in our 
previous work could be used to activate cardiac conditioning, 
and herein report our results, for the ﬁ rst time.
We performed electrical skin stimulation (ES) using 
electroacupuncture needles and current (for technical de-
tails, see the legend of Figure 2) 15 min prior to I/R or at 
the beginning of reperfusion (for 15 min thereafter). For 
ES, an EA needle was not inserted deep into the tissue as 
it is for acupuncture, but was inserted and only hooked 
through the skin (thus, the term ES). Infarct size was used 
to evaluate the results of I/R injury with or without prior 
ES treatments. The results of this study demonstrate that 
ES of speciﬁ c points spaced equally along the line lateral to 
the umbilicus (the same region used for RPCT) induces a 
powerful 80%–85% (P ≤ 0.05) reduction in infarct size when 
applied either as a preconditioning or as a postcondition-
ing stimulus (Figure 2). This result supports the conclusion 
that NIC by ES at the anterior abdominal site is efﬁ cacious 
against I/R injury in the mouse, similar to RPCT. Since this 
intervention works as a postconditioning stimulus, is non-
traumatic, non-ischemic, and does not require surgical in-
tervention, we believe it has great clinical relevance.
Figure 2. Cardiac conditioning by nociceptor activation via electrical skin 
stimulation (ES). Sterile ﬁ nger and facial acupuncture needles (0.18 × 7 mm; 
Millenia Acupuncture, Alhambra, CA, USA) were placed equally on a line through 
the region previously delineated for RPCT [62], connected to a KWD-808-I multi-
purpose health device (Yingdi Inc., China) and stimulated with electricity (10 V 
100 Hz pulse width 400 ms) for 20 min for preconditioning, and then ischemia 
was initiated ((a) Pre-NIC). For (b) post-NIC, the stimulus was initiated just 
prior to reperfusion and continued for 20 min. Needles were removed before 
the mice regained consciousness and reperfusion was for 24 h. At the end of 
reperfusion, the mice were anesthetized and the hearts were cannulated and 
stained, ﬁ xed, photographed, and the infarcts analyzed, as previously detailed 
[42, 62]. Right: Representative TTC stained mid-LV images from sham (top 
and bottom left), pre-NIC (top right), and post-NIC (bottom right). Reduction of 
infarct size was greater than 80% for both pre- and post-NIC.
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5 Conclusions
Nearly three decades of studies have taught us much about 
the mechanisms that underlie the endogenous cardioprotec-
tion afforded by IPC. The discovery of RPCT has offered sig-
niﬁ cant therapeutic strategies for protecting the heart against 
myocardial I/R injury, and opened the door to the explora-
tion of new modalities for triggering cardioprotection. The 
fact that some of these modalities work in multiple model 
species, and in humans [108], supports that these models are 
worthwhile laboratories to further our understanding and 
for preclinical development. Mechanistic and combinatorial 
studies support the hypothesis that preconditioning, percon-
ditioning and postconditioning, as well as IPC, RIPC, nerve 
stimulation, EA, and NIC have many common mechanistic 
components. Yet mechanistic differences remain as well. For 
example, both IPC and RIPC involve the action of TNF-α, 
adenosine, and opioids, and yet these are not involved in 
the mechanism underlying RPCT [62] and NIC [85]. EA has 
been reported to be effective as a preconditioning but not as 
a postconditioning stimulus [41]. Yet all of these modalities 
require and employ the activity of NF-κB, PKC, bradykinin, 
and the mitoKATP channel [42, 62]. We propose that all of 
these cardioprotective phenomena are in fact a reﬂ ection of a 
broader cardiac conditioning network, and that each stimu-
lus works through slightly different initiating points in that 
network (Figure 1). IPC seems to invoke multiple initiating 
points, including vascular, humoral, and neural, while NIC 
and EA work primarily through the neural initiating por-
tions of the network. Differences in initiation may relate to 
differential activation of components of the network; thus, 
their detectable activation, necessity, or dispensability in the 
particular phenomena under study are different. Our view 
of these phenomena as discrete derives primarily from the 
timing over the last 29 years of our experimental discovery of 
the different modalities and the mechanistic pieces. The pro-
posed conditioning network includes: humoral factors; neural 
and vascular signaling; kinase, oxidative, and metabolic cas-
cades in cardiac cells (and perhaps between cells of different 
types); gene expression; and related miRNA networks. As far 
as we can tell, these network components converge at several 
points, including PKC, bradykinin, and the mitochondria. As 
our work progresses, we predict that we will ﬁ nd additional 
components of the network that are more critical for NIC, ES, 
and RIPC, for example, but that are dispensable for IPC. We 
recognize that the existence of such a conditioning network is 
really a human construct that designates parts of the overall 
cellular and intercellular informational network as having a 
speciﬁ c function related to myocardial salvage. However, for 
the purposes of research and translation, such constructs are 
helpful to delineate functions for molecules that may eventu-
ally be considered as therapeutic targets.
There remains a great clinical need for non-ischemic and 
non-traumatic methods to initiate cardiac conditioning. 
At the moment, the discovery of NIC and EA/ES-induced 
neural pathways as remote non-ischemic initiators holds 
great promise for the development of pharmacologic and 
electroceutical approaches [109, 110] to elicit cardioprotection 
without causing ischemia or requiring surgical intervention. 
We demonstrate herein for the ﬁ rst time that NIC is protec-
tive as a postconditioning stimulus, establishing the clinical 
relevance of studying the underlying mechanism and further 
preclinical development.
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